Quantitative analysis of [carbonyl-(11)C]WAY-100635 PET studies.

[carbonyl-(11)C]WAY-100635 ¿[(11)C]N-(2-(4-(2-methoxyphenyl)-1-piperazin-1-yl)ethyl)-N-(2- pyridy l)cyclohexanecarboxamide¿ is a positron-emission tomography (PET) radioligand for in vivo imaging of the 5-hydroxytryptamine(1A) (5-HT(1A)) receptor. This paper assesses and summarises various different modeling strategies for the quantitative analysis of the radioligand. The models considered are based on a compartmental description of the ligands behaviour and include both plasma input analyses, requiring the additional monitoring of blood activity, and a reference tissue approach, which relies solely on the tomographic tissue data. Parameter estimates of specific binding are presented for a set of test-retest data, obtained from six normal volunteers who were scanned on two separate occasions, allowing for an assessment of normal binding values and their reproducibility.

[1]  Richard S. J. Frackowiak,et al.  Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. , 1990, Brain : a journal of neurology.

[2]  M. Mintun,et al.  A quantitative model for the in vivo assessment of drug binding sites with positron emission tomography , 1984, Annals of neurology.

[3]  I A Cliffe,et al.  A pharmacological profile of the selective silent 5-HT1A receptor antagonist, WAY-100635. , 1995, European journal of pharmacology.

[4]  R. V. Van Heertum,et al.  Positron emission tomography study of pindolol occupancy of 5-HT(1A) receptors in humans: preliminary analyses. , 2000, Nuclear Medicine and Biology.

[5]  S. Hume,et al.  Pindolol occupancy of 5‐HT1A receptors measured in vivo using small animal positron emission tomography with carbon‐11 labeled WAY 100635 , 2000, Synapse.

[6]  M. Mintun,et al.  Kinetic Modeling of Serotonin-1A Binding in Monkeys Using [11C]WAY 100635 and PET , 1996 .

[7]  D J Brooks,et al.  Comparison of Methods for Analysis of Clinical [11C]Raclopride Studies , 1996, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[8]  Christer Halldin,et al.  PET Studies of Binding Competition between Endogenous Dopamine and the D1 Radiotracer [11C]NNC 756 , 1998, NeuroImage.

[9]  M. Reivich,et al.  THE [14C]DEOXYGLUCOSE METHOD FOR THE MEASUREMENT OF LOCAL CEREBRAL GLUCOSE UTILIZATION: THEORY, PROCEDURE, AND NORMAL VALUES IN THE CONSCIOUS AND ANESTHETIZED ALBINO RAT 1 , 1977, Journal of neurochemistry.

[10]  Roger N. Gunn,et al.  Tracer Kinetic Modeling of the 5-HT1AReceptor Ligand [carbonyl-11C]WAY-100635 for PET , 1998, NeuroImage.

[11]  M Slifstein,et al.  Derivation of [(11)C]WAY-100635 binding parameters with reference tissue models: effect of violations of model assumptions. , 2000, Nuclear medicine and biology.

[12]  D. Kupfer,et al.  Pet imaging of serotonin 1A receptor binding in depression , 1999, Biological Psychiatry.

[13]  Christer Halldin,et al.  PET-characterization of [carbonyl-11C]WAY-100635 binding to 5-HT1A receptors in the primate brain , 1997, Psychopharmacology.

[14]  A. Lammertsma,et al.  Simplified Reference Tissue Model for PET Receptor Studies , 1996, NeuroImage.

[15]  C. Halldin,et al.  Quantitative analyses of carbonyl-carbon-11-WAY-100635 binding to central 5-hydroxytryptamine-1A receptors in man. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[16]  A A Lammertsma,et al.  Evaluation of [O-methyl-3H]WAY-100635 as an in vivo radioligand for 5-HT1A receptors in rat brain. , 1994, European journal of pharmacology.

[17]  P. Grasby,et al.  Characterisation of the appearance of radioactive metabolites in monkey and human plasma from the 5-HT1A receptor radioligand, [carbonyl-11C]WAY-100635--explanation of high signal contrast in PET and an aid to biomathematical modelling. , 1998, Nuclear medicine and biology.

[18]  Roger N. Gunn,et al.  Pharmacological constraints associated with positron emission tomographic scanning of small laboratory animals , 1998, European Journal of Nuclear Medicine.

[19]  Karl J. Friston,et al.  Multisubject fMRI Studies and Conjunction Analyses , 1999, NeuroImage.

[20]  Marc Laruelle,et al.  Modelling: when and why? , 1999, European Journal of Nuclear Medicine.

[21]  M. Minchin,et al.  Characterisation of the Binding of [3H]WAY‐100635, a Novel 5‐Hydroxytryptamine1A Receptor Antagonist, to Rat Brain , 1995, Journal of neurochemistry.

[22]  P A Sargent,et al.  Exquisite delineation of 5-HT1A receptors in human brain with PET and [carbonyl-11 C]WAY-100635. , 1996, European journal of pharmacology.

[23]  Vincent J. Cunningham,et al.  Parametric Imaging of Ligand-Receptor Binding in PET Using a Simplified Reference Region Model , 1997, NeuroImage.

[24]  H. Wikström,et al.  Autoradiographic localization of 5-HT1A receptors in the post-mortem human brain using [3H]WAY-100635 and [11C]WAY-100635 , 1997, Brain Research.

[25]  P A Sargent,et al.  Brain serotonin1A receptor binding measured by positron emission tomography with [11C]WAY-100635: effects of depression and antidepressant treatment. , 2000, Archives of general psychiatry.

[26]  M. Hamon,et al.  Selective in vivo labelling of brain 5-HT1A receptors by [3H]WAY 100635 in the mouse. , 1994, European journal of pharmacology.

[27]  Ralph Myers,et al.  Assessment of Spatial Normalization of PET Ligand Images Using Ligand-Specific Templates , 1999, NeuroImage.

[28]  S. Kety,et al.  THE NITROUS OXIDE METHOD FOR THE QUANTITATIVE DETERMINATION OF CEREBRAL BLOOD FLOW IN MAN: THEORY, PROCEDURE AND NORMAL VALUES. , 1948, The Journal of clinical investigation.

[29]  Roger N. Gunn,et al.  Small Animal PET Enables Parametric Mapping of Saturation Kinetics at the 5-HT1A Receptor , 2001 .